Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.
Identifieur interne : 000A90 ( Main/Exploration ); précédent : 000A89; suivant : 000A91Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.
Auteurs : David V. Glidden [États-Unis] ; Kathleen Mulligan ; Vanessa Mcmahan ; Peter L. Anderson ; Juan Guanira ; Suwat Chariyalertsak ; Susan P. Buchbinder ; Linda Gail Bekker ; Mauro Schechter ; Beatriz Grinsztejn ; Robert M. GrantSource :
- Journal of acquired immune deficiency syndromes (1999) [ 1944-7884 ] ; 2017.
Descripteurs français
- KwdFr :
- Absorptiométrie photonique, Adulte, Agents antiVIH (administration et posologie), Agents antiVIH (effets indésirables), Densité osseuse (), Emtricitabine (administration et posologie), Femelle, Homosexualité masculine, Humains, Infections à VIH (), Infections à VIH (traitement médicamenteux), Maladies osseuses (), Mâle, Observance thérapeutique, Prophylaxie pré-exposition, Ténofovir (administration et posologie), Ténofovir (effets indésirables), Études de suivi.
- MESH :
- administration et posologie : Agents antiVIH, Emtricitabine, Ténofovir.
- effets indésirables : Agents antiVIH, Ténofovir.
- traitement médicamenteux : Infections à VIH.
- Absorptiométrie photonique, Adulte, Densité osseuse, Femelle, Homosexualité masculine, Humains, Infections à VIH, Maladies osseuses, Mâle, Observance thérapeutique, Prophylaxie pré-exposition, Études de suivi.
English descriptors
- KwdEn :
- Absorptiometry, Photon, Adult, Anti-HIV Agents (administration & dosage), Anti-HIV Agents (adverse effects), Bone Density (drug effects), Bone Diseases (chemically induced), Bone Diseases (therapy), Emtricitabine (administration & dosage), Female, Follow-Up Studies, HIV Infections (complications), HIV Infections (drug therapy), HIV Infections (prevention & control), Homosexuality, Male, Humans, Male, Patient Compliance, Pre-Exposure Prophylaxis, Tenofovir (administration & dosage), Tenofovir (adverse effects).
- MESH :
- chemical , administration & dosage : Anti-HIV Agents, Emtricitabine, Tenofovir.
- chemical , adverse effects : Anti-HIV Agents, Tenofovir.
- chemically induced : Bone Diseases.
- complications : HIV Infections.
- drug effects : Bone Density.
- drug therapy : HIV Infections.
- prevention & control : HIV Infections.
- therapy : Bone Diseases.
- Absorptiometry, Photon, Adult, Female, Follow-Up Studies, Homosexuality, Male, Humans, Male, Patient Compliance, Pre-Exposure Prophylaxis.
Abstract
Oral tenofovir disoproxil fumarate (TDF) for HIV prevention and treatment is associated with decreases in bone mineral density (BMD). Previous reports suggest that these changes may be reversible after discontinuation of TDF.
DOI: 10.1097/QAI.0000000000001475
PubMed: 28639995
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000D09
- to stream PubMed, to step Curation: 000D09
- to stream PubMed, to step Checkpoint: 000D09
- to stream Ncbi, to step Merge: 004308
- to stream Ncbi, to step Curation: 004308
- to stream Ncbi, to step Checkpoint: 004308
- to stream Main, to step Merge: 000A90
- to stream Main, to step Curation: 000A90
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.</title><author><name sortKey="Glidden, David V" sort="Glidden, David V" uniqKey="Glidden D" first="David V" last="Glidden">David V. Glidden</name><affiliation wicri:level="2"><nlm:affiliation>*Departments of Epidemiology and Biostatistics; †Medicine,University of California, San Francisco, San Francisco, CA; ‡Department of Health Services, University of Washington, Seattle, WA; §Department of Pharmaceutical Sciences, University of Colorado, Denver, Aurora, CO; ∥Investigaciones Médicas en Salud, Lima, Peru; ¶Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand; #Bridge HIV, San Francisco Department of Public Health, San Francisco, CA; **Department of Medicine, Desmond Tutu HIV Foundation, Cape Town, South Africa; ††Projeto Praça Onze, Hospital Escola São Francisco de Assis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; ‡‡Evandro Chagas National Institute of Infectious Diseases-Fiocruz, Rio de Janeiro, Brazil; and §§Gladstone Institute of Virology and San Francisco AIDS Foundation, San Francisco, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>*Departments of Epidemiology and Biostatistics; †Medicine,University of California, San Francisco, San Francisco, CA; ‡Department of Health Services, University of Washington, Seattle, WA; §Department of Pharmaceutical Sciences, University of Colorado, Denver, Aurora, CO; ∥Investigaciones Médicas en Salud, Lima, Peru; ¶Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand; #Bridge HIV, San Francisco Department of Public Health, San Francisco, CA; **Department of Medicine, Desmond Tutu HIV Foundation, Cape Town, South Africa; ††Projeto Praça Onze, Hospital Escola São Francisco de Assis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; ‡‡Evandro Chagas National Institute of Infectious Diseases-Fiocruz, Rio de Janeiro, Brazil; and §§Gladstone Institute of Virology and San Francisco AIDS Foundation, San Francisco</wicri:cityArea></affiliation></author><author><name sortKey="Mulligan, Kathleen" sort="Mulligan, Kathleen" uniqKey="Mulligan K" first="Kathleen" last="Mulligan">Kathleen Mulligan</name></author><author><name sortKey="Mcmahan, Vanessa" sort="Mcmahan, Vanessa" uniqKey="Mcmahan V" first="Vanessa" last="Mcmahan">Vanessa Mcmahan</name></author><author><name sortKey="Anderson, Peter L" sort="Anderson, Peter L" uniqKey="Anderson P" first="Peter L" last="Anderson">Peter L. Anderson</name></author><author><name sortKey="Guanira, Juan" sort="Guanira, Juan" uniqKey="Guanira J" first="Juan" last="Guanira">Juan Guanira</name></author><author><name sortKey="Chariyalertsak, Suwat" sort="Chariyalertsak, Suwat" uniqKey="Chariyalertsak S" first="Suwat" last="Chariyalertsak">Suwat Chariyalertsak</name></author><author><name sortKey="Buchbinder, Susan P" sort="Buchbinder, Susan P" uniqKey="Buchbinder S" first="Susan P" last="Buchbinder">Susan P. Buchbinder</name></author><author><name sortKey="Bekker, Linda Gail" sort="Bekker, Linda Gail" uniqKey="Bekker L" first="Linda Gail" last="Bekker">Linda Gail Bekker</name></author><author><name sortKey="Schechter, Mauro" sort="Schechter, Mauro" uniqKey="Schechter M" first="Mauro" last="Schechter">Mauro Schechter</name></author><author><name sortKey="Grinsztejn, Beatriz" sort="Grinsztejn, Beatriz" uniqKey="Grinsztejn B" first="Beatriz" last="Grinsztejn">Beatriz Grinsztejn</name></author><author><name sortKey="Grant, Robert M" sort="Grant, Robert M" uniqKey="Grant R" first="Robert M" last="Grant">Robert M. Grant</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28639995</idno><idno type="pmid">28639995</idno><idno type="doi">10.1097/QAI.0000000000001475</idno><idno type="wicri:Area/PubMed/Corpus">000D09</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D09</idno><idno type="wicri:Area/PubMed/Curation">000D09</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000D09</idno><idno type="wicri:Area/PubMed/Checkpoint">000D09</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000D09</idno><idno type="wicri:Area/Ncbi/Merge">004308</idno><idno type="wicri:Area/Ncbi/Curation">004308</idno><idno type="wicri:Area/Ncbi/Checkpoint">004308</idno><idno type="wicri:Area/Main/Merge">000A90</idno><idno type="wicri:Area/Main/Curation">000A90</idno><idno type="wicri:Area/Main/Exploration">000A90</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.</title><author><name sortKey="Glidden, David V" sort="Glidden, David V" uniqKey="Glidden D" first="David V" last="Glidden">David V. Glidden</name><affiliation wicri:level="2"><nlm:affiliation>*Departments of Epidemiology and Biostatistics; †Medicine,University of California, San Francisco, San Francisco, CA; ‡Department of Health Services, University of Washington, Seattle, WA; §Department of Pharmaceutical Sciences, University of Colorado, Denver, Aurora, CO; ∥Investigaciones Médicas en Salud, Lima, Peru; ¶Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand; #Bridge HIV, San Francisco Department of Public Health, San Francisco, CA; **Department of Medicine, Desmond Tutu HIV Foundation, Cape Town, South Africa; ††Projeto Praça Onze, Hospital Escola São Francisco de Assis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; ‡‡Evandro Chagas National Institute of Infectious Diseases-Fiocruz, Rio de Janeiro, Brazil; and §§Gladstone Institute of Virology and San Francisco AIDS Foundation, San Francisco, CA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>*Departments of Epidemiology and Biostatistics; †Medicine,University of California, San Francisco, San Francisco, CA; ‡Department of Health Services, University of Washington, Seattle, WA; §Department of Pharmaceutical Sciences, University of Colorado, Denver, Aurora, CO; ∥Investigaciones Médicas en Salud, Lima, Peru; ¶Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand; #Bridge HIV, San Francisco Department of Public Health, San Francisco, CA; **Department of Medicine, Desmond Tutu HIV Foundation, Cape Town, South Africa; ††Projeto Praça Onze, Hospital Escola São Francisco de Assis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; ‡‡Evandro Chagas National Institute of Infectious Diseases-Fiocruz, Rio de Janeiro, Brazil; and §§Gladstone Institute of Virology and San Francisco AIDS Foundation, San Francisco</wicri:cityArea></affiliation></author><author><name sortKey="Mulligan, Kathleen" sort="Mulligan, Kathleen" uniqKey="Mulligan K" first="Kathleen" last="Mulligan">Kathleen Mulligan</name></author><author><name sortKey="Mcmahan, Vanessa" sort="Mcmahan, Vanessa" uniqKey="Mcmahan V" first="Vanessa" last="Mcmahan">Vanessa Mcmahan</name></author><author><name sortKey="Anderson, Peter L" sort="Anderson, Peter L" uniqKey="Anderson P" first="Peter L" last="Anderson">Peter L. Anderson</name></author><author><name sortKey="Guanira, Juan" sort="Guanira, Juan" uniqKey="Guanira J" first="Juan" last="Guanira">Juan Guanira</name></author><author><name sortKey="Chariyalertsak, Suwat" sort="Chariyalertsak, Suwat" uniqKey="Chariyalertsak S" first="Suwat" last="Chariyalertsak">Suwat Chariyalertsak</name></author><author><name sortKey="Buchbinder, Susan P" sort="Buchbinder, Susan P" uniqKey="Buchbinder S" first="Susan P" last="Buchbinder">Susan P. Buchbinder</name></author><author><name sortKey="Bekker, Linda Gail" sort="Bekker, Linda Gail" uniqKey="Bekker L" first="Linda Gail" last="Bekker">Linda Gail Bekker</name></author><author><name sortKey="Schechter, Mauro" sort="Schechter, Mauro" uniqKey="Schechter M" first="Mauro" last="Schechter">Mauro Schechter</name></author><author><name sortKey="Grinsztejn, Beatriz" sort="Grinsztejn, Beatriz" uniqKey="Grinsztejn B" first="Beatriz" last="Grinsztejn">Beatriz Grinsztejn</name></author><author><name sortKey="Grant, Robert M" sort="Grant, Robert M" uniqKey="Grant R" first="Robert M" last="Grant">Robert M. Grant</name></author></analytic><series><title level="j">Journal of acquired immune deficiency syndromes (1999)</title><idno type="eISSN">1944-7884</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Absorptiometry, Photon</term><term>Adult</term><term>Anti-HIV Agents (administration & dosage)</term><term>Anti-HIV Agents (adverse effects)</term><term>Bone Density (drug effects)</term><term>Bone Diseases (chemically induced)</term><term>Bone Diseases (therapy)</term><term>Emtricitabine (administration & dosage)</term><term>Female</term><term>Follow-Up Studies</term><term>HIV Infections (complications)</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (prevention & control)</term><term>Homosexuality, Male</term><term>Humans</term><term>Male</term><term>Patient Compliance</term><term>Pre-Exposure Prophylaxis</term><term>Tenofovir (administration & dosage)</term><term>Tenofovir (adverse effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Absorptiométrie photonique</term><term>Adulte</term><term>Agents antiVIH (administration et posologie)</term><term>Agents antiVIH (effets indésirables)</term><term>Densité osseuse ()</term><term>Emtricitabine (administration et posologie)</term><term>Femelle</term><term>Homosexualité masculine</term><term>Humains</term><term>Infections à VIH ()</term><term>Infections à VIH (traitement médicamenteux)</term><term>Maladies osseuses ()</term><term>Mâle</term><term>Observance thérapeutique</term><term>Prophylaxie pré-exposition</term><term>Ténofovir (administration et posologie)</term><term>Ténofovir (effets indésirables)</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-HIV Agents</term><term>Emtricitabine</term><term>Tenofovir</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anti-HIV Agents</term><term>Tenofovir</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Agents antiVIH</term><term>Emtricitabine</term><term>Ténofovir</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Bone Diseases</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Bone Density</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Agents antiVIH</term><term>Ténofovir</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Bone Diseases</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Absorptiometry, Photon</term><term>Adult</term><term>Female</term><term>Follow-Up Studies</term><term>Homosexuality, Male</term><term>Humans</term><term>Male</term><term>Patient Compliance</term><term>Pre-Exposure Prophylaxis</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Absorptiométrie photonique</term><term>Adulte</term><term>Densité osseuse</term><term>Femelle</term><term>Homosexualité masculine</term><term>Humains</term><term>Infections à VIH</term><term>Maladies osseuses</term><term>Mâle</term><term>Observance thérapeutique</term><term>Prophylaxie pré-exposition</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Oral tenofovir disoproxil fumarate (TDF) for HIV prevention and treatment is associated with decreases in bone mineral density (BMD). Previous reports suggest that these changes may be reversible after discontinuation of TDF.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><noCountry><name sortKey="Anderson, Peter L" sort="Anderson, Peter L" uniqKey="Anderson P" first="Peter L" last="Anderson">Peter L. Anderson</name><name sortKey="Bekker, Linda Gail" sort="Bekker, Linda Gail" uniqKey="Bekker L" first="Linda Gail" last="Bekker">Linda Gail Bekker</name><name sortKey="Buchbinder, Susan P" sort="Buchbinder, Susan P" uniqKey="Buchbinder S" first="Susan P" last="Buchbinder">Susan P. Buchbinder</name><name sortKey="Chariyalertsak, Suwat" sort="Chariyalertsak, Suwat" uniqKey="Chariyalertsak S" first="Suwat" last="Chariyalertsak">Suwat Chariyalertsak</name><name sortKey="Grant, Robert M" sort="Grant, Robert M" uniqKey="Grant R" first="Robert M" last="Grant">Robert M. Grant</name><name sortKey="Grinsztejn, Beatriz" sort="Grinsztejn, Beatriz" uniqKey="Grinsztejn B" first="Beatriz" last="Grinsztejn">Beatriz Grinsztejn</name><name sortKey="Guanira, Juan" sort="Guanira, Juan" uniqKey="Guanira J" first="Juan" last="Guanira">Juan Guanira</name><name sortKey="Mcmahan, Vanessa" sort="Mcmahan, Vanessa" uniqKey="Mcmahan V" first="Vanessa" last="Mcmahan">Vanessa Mcmahan</name><name sortKey="Mulligan, Kathleen" sort="Mulligan, Kathleen" uniqKey="Mulligan K" first="Kathleen" last="Mulligan">Kathleen Mulligan</name><name sortKey="Schechter, Mauro" sort="Schechter, Mauro" uniqKey="Schechter M" first="Mauro" last="Schechter">Mauro Schechter</name></noCountry><country name="États-Unis"><region name="Californie"><name sortKey="Glidden, David V" sort="Glidden, David V" uniqKey="Glidden D" first="David V" last="Glidden">David V. Glidden</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A90 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A90 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28639995
|texte= Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28639995" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |